Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Julia Elisabeth Fromme

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 22, 2021
Sequencing of immunotherapy and targeted therapy for BRAF<sup>V600</sup> mutated melanoma: a retrospective studyOana-Diana Persa, Julia Elisabeth Fromme, Cornelia Mauch
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2021
Oana-Diana Persa, Julia Elisabeth Fromme, Cornelia Mauch
Experimental Dermatology|November 28, 2022
Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapyJulia Elisabeth Fromme, Reinhard Dummer, Cornelia Mauch, et al.
Oncotarget|September 6, 2018
FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosisJulia Elisabeth Fromme, Katja Schmitz, Astrid Wachter, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|February 22, 2021
Sequencing of immunotherapy and targeted therapy for BRAF<sup>V600</sup> mutated melanoma: a retrospective studyOana-Diana Persa, Julia Elisabeth Fromme, Cornelia Mauch
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 17, 2021
Oana-Diana Persa, Julia Elisabeth Fromme, Cornelia Mauch
Experimental Dermatology|November 28, 2022
Tenascin C is a valuable marker for melanoma progression independent of mutational status and MAPK inhibitor therapyJulia Elisabeth Fromme, Reinhard Dummer, Cornelia Mauch, et al.
Oncotarget|September 6, 2018
FGFR3 mRNA overexpression defines a subset of oligometastatic colorectal cancers with worse prognosisJulia Elisabeth Fromme, Katja Schmitz, Astrid Wachter, et al.
Pageof 1